Univest
Univest
  • Markets

3 Pathology Labs Network, Digital Engineering Firm and Stainless Pipes Maker Stocks With a Strong Future Roadmap: Thyrocare Technologies, Zensar Technologies and Ratnamani Metals and Tubes

  • November 17, 2026
  • Posted by: Harsh Piplani
  • Category: Best Stocks
No Comments
3 Pathology Labs Network, Digital Engineering Firm and Stainless Pipes Maker Stocks With a Strong Future Roadmap: Thyrocare Technologies, Zensar Technologies and Ratnamani Metals and Tubes

Thyrocare Technologies, Zensar Technologies and Ratnamani Metals and Tubes: ROE of 11.7% to 27.9% and FY22 to FY26 revenue CAGR of 7.8% to 9.8%. Prices as of 16 Nov 2026.

Quick Answer

The three blood test lab, IT service and steel pipe stocks to watch are Thyrocare Technologies, Zensar Technologies and Ratnamani Metals and Tubes. Their return on equity ranges from 11.7% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.8% to 9.8%. Thyrocare Technologies has the highest return on equity at 27.9%, while Ratnamani Metals and Tubes has the fastest revenue growth at 9.8% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.

Blood test lab, IT service and steel pipe stocks let investors follow companies that serve a growing part of the Indian economy. Thyrocare Technologies, Zensar Technologies and Ratnamani Metals and Tubes cover a diagnostics labs company, an IT services company and a steel pipes and tubes maker.

This list covers three blood test lab, IT service and steel pipe stocks with complete current figures: Thyrocare Technologies, Zensar Technologies and Ratnamani Metals and Tubes. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Blood Test Lab, IT Service and Steel Pipe Stocks?
  • Blood Test Lab, IT Service and Steel Pipe Stocks at a Glance
  • Why Do Blood Test Lab, IT Service and Steel Pipe Stocks Have a Strong Roadmap in India?
  • Why Thyrocare Technologies Features Among These Blood Test Lab, IT Service and Steel Pipe Stocks
  • Why Zensar Technologies Features Among These Blood Test Lab, IT Service and Steel Pipe Stocks
  • Why Ratnamani Metals and Tubes Features Among These Blood Test Lab, IT Service and Steel Pipe Stocks
  • Thyrocare Technologies vs Zensar Technologies vs Ratnamani Metals and Tubes on Key Financials
  • Key Risks to Check Before Investing in Blood Test Lab, IT Service and Steel Pipe Stocks
  • Final Thoughts on Blood Test Lab, IT Service and Steel Pipe Stocks
    • What are blood test lab, IT service and steel pipe stocks?
    • Which blood test lab, IT service and steel pipe stocks are covered in this list?
    • Why do blood test lab, IT service and steel pipe stocks have a strong future roadmap in India?
    • How has Thyrocare Technologies performed financially?
    • How has Zensar Technologies performed financially?
    • How has Ratnamani Metals and Tubes performed financially?
    • What risks should investors check before buying blood test lab, IT service and steel pipe stocks?
    • Is this list of blood test lab, IT service and steel pipe stocks investment advice?

What Are Blood Test Lab, IT Service and Steel Pipe Stocks?

Blood test lab, IT service and steel pipe stocks are listed companies that run diagnostic labs and test collection centres across India, provide IT and digital engineering services to global clients, and make stainless steel and carbon steel pipes and tubes for oil, gas and power plants. Their earnings depend on test volumes, client technology budgets and project orders.

Blood Test Lab, IT Service and Steel Pipe Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Thyrocare Technologies 509.65 7,501 42.6 59.6 27.9 0.09
Zensar Technologies 539.1 11,686 15.1 17.5 16.4 0.02
Ratnamani Metals and Tubes 2,435.4 17,569 34.2 44.4 11.7 0.08

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing blood test lab, IT service and steel pipe stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in blood test lab, IT service and steel pipe stocks can use the coming numbers to test whether growth is holding.

Why Do Blood Test Lab, IT Service and Steel Pipe Stocks Have a Strong Roadmap in India?

Blood test lab, IT service and steel pipe stocks have a strong roadmap in India because wider use of preventive health tests, rising client spending on digital work and large energy projects keep widening the market for these companies.

  • Diagnostics. Preventive health tests are more common.
  • IT services. Clients spend on digital engineering.
  • Steel pipes. Energy plants need quality tubes.

Why Thyrocare Technologies Features Among These Blood Test Lab, IT Service and Steel Pipe Stocks

Among the blood test lab, IT service and steel pipe stocks on this list, Thyrocare Technologies runs a centralised, high-volume testing laboratory in Navi Mumbai and collects samples through a wide partner network of diagnostic centres, pharmacies and franchisees across India.

In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%.

Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6.

Roadmap: The centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.

What to watch: Track growth in test volume per day and the share of revenue from preventive health packages.

Why Zensar Technologies Features Among These Blood Test Lab, IT Service and Steel Pipe Stocks

Among the pathology chain, software exporter and stainless tube shares on this list, Zensar Technologies, an RPG group company, offers digital engineering, cloud and experience services to clients across financial services, retail and manufacturing.

The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 11,686 crore. The stock trades at a P/E of 15.1, below the industry P/E of 17.5.

Revenue rose from Rs 4,382 crore in FY22 to Rs 5,921 crore in FY26, a compound annual growth rate of 7.8%. Net profit grew from Rs 422 crore in FY22 to Rs 775 crore in FY26, which works out to a compound annual growth rate of 16.4%. In the June 2026 quarter, revenue grew 8.6% year on year to Rs 1,566 crore, while net profit rose 1.0% to Rs 184 crore.

Roadmap: Strong deal wins in cloud and data work, a focus on fewer, larger clients and the use of artificial intelligence in delivery support its path. Cost discipline has allowed margins to improve over the years.

What to watch: Follow client concentration and growth in large accounts.

Why Ratnamani Metals and Tubes Features Among These Blood Test Lab, IT Service and Steel Pipe Stocks

Among the three companies on this list, Ratnamani Metals and Tubes makes stainless steel and carbon steel pipes and tubes for oil and gas, power, chemicals, fertilisers and nuclear applications, selling in India and overseas.

Revenue rose from Rs 3,176 crore in FY22 to Rs 4,616 crore in FY26, a compound annual growth rate of 9.8%. Net profit grew from Rs 323 crore in FY22 to Rs 534 crore in FY26, which works out to a compound annual growth rate of 13.4%.

The company has a return on equity of 11.7%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 17,569 crore. The stock trades at a P/E of 34.2, below the industry P/E of 44.4.

Roadmap: The company is a specialist in demanding tube applications and holds a strong order book across energy and process industries. Capacity additions in welded pipes and a growing export presence extend its reach.

What to watch: Check the size of the order book and its execution through the year.

Thyrocare Technologies vs Zensar Technologies vs Ratnamani Metals and Tubes on Key Financials

The table below sets the three blood test lab, IT service and steel pipe stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Thyrocare Technologies 618 846 8.2% 163 19.2%
Zensar Technologies 4,382 5,921 7.8% 775 13.1%
Ratnamani Metals and Tubes 3,176 4,616 9.8% 534 11.6%

Thyrocare Technologies posts the highest return on equity in this group at 27.9%. Zensar Technologies has the largest FY26 revenue at Rs 5,921 crore, and Ratnamani Metals and Tubes shows the fastest revenue growth with a 9.8% compound annual rate. A useful habit with blood test lab, IT service and steel pipe stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several diagnostics, digital engineering and pipes stocks instead of one name, which keeps a single result from deciding the outcome.

Key Risks to Check Before Investing in Blood Test Lab, IT Service and Steel Pipe Stocks

Every theme carries risks that deserve a check before any decision. For these blood test lab, IT service and steel pipe stocks, the main points are: Long-term pathology chain, software exporter and stainless tube shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio. Tracking promoter holding and management commentary adds context when you study pathology chain, software exporter and stainless tube shares.

  • Test volumes. Footfall and test mix can vary with seasons.
  • Client spending. Technology budgets can vary with global conditions.
  • Order timing. Project awards can shift between periods.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter blood test lab, IT service and steel pipe stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Blood Test Lab, IT Service and Steel Pipe Stocks

Blood test lab, IT service and steel pipe stocks reward investors who follow demand trends, order books and margins together. Thyrocare Technologies, Zensar Technologies and Ratnamani Metals and Tubes each have a clear plan to grow. Based on the 16 November 2026 close, Thyrocare Technologies trades at Rs 509.65, Zensar Technologies at Rs 539.1 and Ratnamani Metals and Tubes at Rs 2,435.4. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these blood test lab, IT service and steel pipe stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track blood test lab, IT service and steel pipe stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are blood test lab, IT service and steel pipe stocks?

Ans. Blood test lab, IT service and steel pipe stocks are listed companies that run diagnostic labs and test collection centres across India, provide IT and digital engineering services to global clients, and make stainless steel and carbon steel pipes and tubes for oil, gas and power plants. Their earnings depend on test volumes, client technology budgets and project orders. This list looks at three of them, Thyrocare Technologies, Zensar Technologies and Ratnamani Metals and Tubes, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.

Which blood test lab, IT service and steel pipe stocks are covered in this list?

Ans. This list covers Thyrocare Technologies, Zensar Technologies and Ratnamani Metals and Tubes. Based on the 16 November 2026 close, Thyrocare Technologies traded at Rs 509.65, Zensar Technologies at Rs 539.1 and Ratnamani Metals and Tubes at Rs 2,435.4. Their return on equity ranges from 11.7% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.8% to 9.8%.

Why do blood test lab, IT service and steel pipe stocks have a strong future roadmap in India?

Ans. Blood test lab, IT service and steel pipe stocks have a strong roadmap in India because wider use of preventive health tests, rising client spending on digital work and large energy projects keep widening the market for these companies. The main drivers are as follows. Diagnostics. Preventive health tests are more common. IT services. Clients spend on digital engineering. Steel pipes. Energy plants need quality tubes. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Thyrocare Technologies performed financially?

Ans. Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6. Looking ahead, the centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.

How has Zensar Technologies performed financially?

Ans. Revenue rose from Rs 4,382 crore in FY22 to Rs 5,921 crore in FY26, a compound annual growth rate of 7.8%. Net profit grew from Rs 422 crore in FY22 to Rs 775 crore in FY26, which works out to a compound annual growth rate of 16.4%. In the June 2026 quarter, revenue grew 8.6% year on year to Rs 1,566 crore, while net profit rose 1.0% to Rs 184 crore. The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 11,686 crore. The stock trades at a P/E of 15.1, below the industry P/E of 17.5. Looking ahead, strong deal wins in cloud and data work, a focus on fewer, larger clients and the use of artificial intelligence in delivery support its path. Cost discipline has allowed margins to improve over the years.

How has Ratnamani Metals and Tubes performed financially?

Ans. Revenue rose from Rs 3,176 crore in FY22 to Rs 4,616 crore in FY26, a compound annual growth rate of 9.8%. Net profit grew from Rs 323 crore in FY22 to Rs 534 crore in FY26, which works out to a compound annual growth rate of 13.4%. The company has a return on equity of 11.7%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 17,569 crore. The stock trades at a P/E of 34.2, below the industry P/E of 44.4. Looking ahead, the company is a specialist in demanding tube applications and holds a strong order book across energy and process industries. Capacity additions in welded pipes and a growing export presence extend its reach.

What risks should investors check before buying blood test lab, IT service and steel pipe stocks?

Ans. Investors should check a few risks before buying blood test lab, IT service and steel pipe stocks. Test volumes. Footfall and test mix can vary with seasons. Client spending. Technology budgets can vary with global conditions. Order timing. Project awards can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of blood test lab, IT service and steel pipe stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



Best Stocks blood test lab diagnostics digital engineering and pipes stocks IT service and steel pipe stocks pathology chain Ratnamani Metals and Tubes software exporter and stainless tube shares Thyrocare Technologies Zensar Technologies
Author: Harsh Piplani
I am Harsh Piplani, an Assistant Content Manager with over 5 years of experience in crafting impactful, result-driven content. I hold a B.Com (Hons) degree and have worked across diverse industries, including education, fintech, healthcare, jewellery, and more. I specialise in content strategy, SEO, and optimisation, ensuring that every piece I create is not just well-written but also well-ranked. I believe content should do more than fill space so as to drive traffic, build authority, and support business growth. I enjoy turning complex ideas into clear, engaging narratives, and, as I like to say, I know how to spin words like a web to influence, structured, strategic, and impossible to ignore. For me, great content sits at the intersection of creativity and performance.

Leave a Reply Cancel reply